Clinical Trials on Non-squamous NSCLC in France

Total 2411 results

Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy (PYRAMID-1)

Non-squamous NSCLC | HER2 Exon 20 Mutation

Korea, Republic of, United States, Taiwan, Belgium, Spain, China, Australia, Turkey, Italy, France, Germany, Poland, Russian Federation
Clovis Oncology, Inc.

Terminated

A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Small Cell Lung Cancer | Non-Small Cell Lung Cancer | NSCLC | Lung Cancer | Metastatic Lung Cancer | SCLC | Stage IV Lung Cancer | Advanced Lung Cancer | Squamous Non-Small Cell Lung Cancer

United States, Italy, Germany, France, Spain
Sanofi

Active, not recruiting

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05)

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Spain, United States, Brazil, Chile, Czechia, France, Hungary, Israel
Hoffmann-La Roche

Active, not recruiting

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

Metastatic Melanoma | Non-small Cell Lung Cancer (NSCLC) | Solid Tumors | Esophageal Squamous Cell Carcinoma (ESCC) | Small Cell Lung Cancer (SCLC)

United States, Korea, Republic of, Denmark, France, Spain, New Zealand
Intergroupe Francophone de Cancerologie Thoracique
Bristol-Myers Squibb; Pierre Fabre Laboratories; Ligue contre le cancer, France

Completed

Chemoradiotherapy of NSCLC Stage IIIB

NSCLC Stage IIIB | Concomitant Radiochemotherapy

France
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study (Pulse)

Metastatic Non-squamous Lung Cancer

France
Centre Oscar Lambret
University Hospital, Lille

Terminated

Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation (CONCORDE)

Nsclc

France
Centre Hospitalier Universitaire de Nīmes
MEDEXPRIM; GRATICULE

Completed

Predicting Response to PD-1 Checkpoint Blockade Using Deep Learning Analysis of Imaging and Clinical Data (Onc AI)

Non-small Cell Lung Cancer (NSCLC)

France
Genmab
BioNTech SE

Recruiting

GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors

Melanoma | Malignant Solid Tumor | Non Small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Head and Neck Squamous Cell Carcinoma (HNSCC) | Colorectal Cancer (CRC)

United States, Taiwan, Spain, Israel, Korea, Republic of, France, Italy, Denmark, Germany, United Kingdom, Georgia, Moldova, Republic of
Institut Claudius Regaud
Merck KGaA, Darmstadt, Germany

Completed

Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer

Locally Advanced Non Small Cell Lung Cancer (NSCLC)

France
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study (IMAHTEP)

NSCLC

France
Navire Pharma Inc., a BridgeBio company
Amgen

Recruiting

SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation (Argonaut)

Non Small Cell Lung Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Metastatic NSCLC

Spain, Australia, France, Denmark, Greece, Italy, Netherlands
Amgen

No longer available

Expanded Access of Sotorasib

Non Small-cell Lung Cancer | Locally Advanced Unresectable NSCLC | Locally Advanced Metastatic NSCLC

United States, Taiwan, Israel, Saudi Arabia, Brazil, Argentina
iTeos Belgium SA

Recruiting

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Metastatic NSCLC | Stage III NSCLC

United States, Belgium, Spain, Switzerland, Italy, France, Canada, Poland, Czechia
Pfizer

Completed

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC

United States, Canada, Australia, Taiwan, Singapore, Japan, Korea, Republic of, Spain, Belgium, Switzerland, France, Germany, Hong Kong, Italy
University Hospital, Brest

Completed

Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer (IMMUNOBZH)

NSCLC

France
Sanofi
Regeneron Pharmaceuticals

Completed

Comparative Efficacy of Cemiplimab to Historical Standard of Care in France (TOSCA)

Cancer/Squamous Cell Carcinoma of Skin

France
Centre Hospitalier Universitaire de Nice

Completed

In Vivo Damage Induced bu UV in the Epidermis of the Scalp

Squamous Cell Carcinomas

France
ETOP IBCSG Partners Foundation
Mirati Therapeutics Inc.

Recruiting

Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status (ADEPPT)

NSCLC Stage IV | KRAS P.G12C

Ireland, Italy, France, Spain, United Kingdom, Belgium
Hospices Civils de Lyon

Completed

Local Control After Robot-assisted Supraglottic Laryngectomy

Supraglottic Squamous Cell Carcinoma

France
Bristol-Myers Squibb

No longer available

Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169)

Non-squamous Non-Small Cell Lung Cancer | Squamous Non-Small Cell Lung Cancer

Brazil, Canada
University Hospital, Montpellier

Recruiting

Residual Disease Evaluation of Resected NSCLC by cirDNA Analysis (LUNGDOC)

Nsclc

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)

NSCLC

France
National Cancer Institute (NCI)

Recruiting

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
Merus N.V.
Chiltern International Inc.; Q2 Solutions; Oncology Therapeutic Development (OTD) and other collaborators

Recruiting

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Gastric Cancer | Colorectal Cancer | NSCLC | Head and Neck Squamous Cell Carcinoma | HNSCC | Advanced/Metastatic Solid Tumors | Gastroesophageal-junction Cancer

United States, Spain, Belgium, France, Netherlands, United Kingdom
Adlai Nortye Biopharma Co., Ltd.
Merck Sharp & Dohme LLC

Active, not recruiting

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Cervical Cancer | Triple-negative Breast Cancer | NSCLC, Squamous or Non-Squamous | Urothelial Carcinoma of the Bladder | Microsatellite Stable (MSS) Colorectal Cancer (CRC)

United States, France
Centre Antoine Lacassagne
GERCOR - Multidisciplinary Oncology Cooperative Group; GORTEC

Withdrawn

Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) (PICH)

Head and Neck Squamous Cell Carcinoma (HNSCC)

France
Genentech, Inc.

Completed

A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

United States, France, Netherlands
CHU de Reims

Completed

Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed (IPPEM)

Patients With Non-small Cell Lung Cancer (NSCLC) and Pleural Mesothelioma and Treated With a Pemetrexed-based Chemotherapy

France
Centre Antoine Lacassagne

Completed

Cetuximab for Unresectable Cutaneous Squamous Cell Carcinoma - A National Retrospective Study (C3)

Squamous Cell Cutaneous Carcinoma of the Skin

France
Institut de cancérologie Strasbourg Europe
Hôpitaux Universitaires de Strasbourg

Recruiting

Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) (OPPIDOM)

Squamous Cell Carcinoma of Head and Neck | Oropharyngeal Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma

France
Rennes University Hospital

Completed

One-step Nucleic Acid Amplification for Detecting Lymph Node Metastasis of Head and Neck Squamous Cell Carcinoma (OSNA-ORL)

cN0 Oral Squamous Cell Carcinomas

France
Fondation Hôpital Saint-Joseph

Not yet recruiting

Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies (iMonitORL)

Squamous Cell Carcinoma of the Oropharynx

France
Institut Bergonié

Completed

Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms (FCRVADS)

Upper Gingival Squamous Cell Carcinoma

France
Assistance Publique - Hôpitaux de Paris
National Cancer Institute (NCI); Canceropôle Ile de France

Completed

Comprehensive Geriatric Assessment and Head and Neck Elderly Cancer Patients (EGéSOR)

Head and Neck Squamous Cell Carcinomas (HNSCCs)

France
Assistance Publique Hopitaux De Marseille

Completed

Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM (NVB Metro)

Non Small Cell Lung Cancer (NSCLC) | Malignant Pleural Mesothelioma (MPM)

France
Centre Henri Becquerel

Unknown

Detection of Circulating Tumor DNA in p16- Locally Advanced Head Neck Squamous Cell Carcinoma (PERSO-NECK)

Head and Neck Squamous Cell Carcinoma

France
Centre Francois Baclesse
GFPC

Recruiting

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018)

ALK Gene Rearrangement Positive | NSCLC Stage IV | NSCLC Stage IIIB | EGFR Gene Mutation | ROS1 Gene Mutation

France
University Hospital, Strasbourg, France

Recruiting

Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.

NSCLC | IMMUNOTHERAPY | QUANTIFICATION OF CELL-FREE DNA

France
Groupe Hospitalier Paris Saint Joseph

Active, not recruiting

Study of the Association Between Tumor Microenvironment Macrophages and Treatment Response in Squamous Cell Carcinoma of the Anal Canal (MACARAN)

Squamous Cell Carcinoma

France
University Hospital, Lille

Completed

Comparison of Voice Results at 5 Years of Treatment of Glottic Squamous Cell Carcinoma T1 by Surgery Versus Radiotherapy (VO Qual)

Glottic Carcinoma

France
Groupe Oncologie Radiotherapie Tete et Cou
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC (ELAN-RT)

Head and Neck Squamous Cell Carcinoma

France, Monaco
Merck KGaA, Darmstadt, Germany

Terminated

EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

France
Sanofi

Completed

Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

France
Groupe Oncologie Radiotherapie Tete et Cou
For Drug Consulting; Eurofins

Recruiting

A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP)

Squamous Cell Carcinoma of Head and Neck

France
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC (PembroRad)

Squamous Cell Carcinoma of the Head and Neck

France
Institut du Cancer de Montpellier - Val d'Aurelle

Active, not recruiting

Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer (SIMPA01)

Head and Neck Squamous Cell Carcinoma

France
University Hospital, Strasbourg, France

Not yet recruiting

High Throughput Screening Device Based on 3D Nano-matrices and 3D Tumors With Functional Vascularization (TUMOVASC)

NSCLC

France
Centre Henri Becquerel

Unknown

Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma (HYPONECK)

Squamous Cell Carcinoma of the Oropharynx

France
Institut de cancérologie Strasbourg Europe
Institut National de la Santé Et de la Recherche Médicale, France; Centre National...

Recruiting

Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma (IPRICE)

Head and Neck Cancer

France

Clinical Trials on Non-squamous NSCLC in France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations